$GPCR News

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Structure Therapeutics Amends And Restates Sales Agreement With Leerink Partners LLC And Cantor Fitzgerald & Co. On May 7, 2026; Increases ATM Shares Offering By $150M To Aggregate $400M

Structure Therapeutics Q1 EPS $(0.35), Inline

Why Structure Therapeutics (GPCR) Is Down 7.2% After Strong Oral GLP-1 Phase 2 Data And FDA Plans

Here is Why Structure Therapeutics (GPCR) is One of the Top Biotech Names to Look at

Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions

Canaccord Genuity Initiates Coverage On Structure Therapeutics with Buy Rating, Announces Price Target of $101

Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel

Structure Therapeutics Appoints Matthew Lang COO

Structure Therapeutics: The Oral Obesity Inflection, Best-In-Class Efficacy Meets Biased-Agonism Safety Moat

Structure Therapeutics: A High-Risk, High-Reward Bet On The Next GLP-1 Blockbuster

Structure Therapeutics' GLP-1 Agonist Could Be A Potential Acquisition Target

Structure Therapeutics Inc. (GPCR) Discusses Positive Topline Results from ACCESS II and Related Studies of Aleniglipron Oral GLP-1 - Slideshow

Structure Therapeutics Inc. (GPCR) Discusses Positive Topline Results from ACCESS II and Related Studies of Aleniglipron Oral GLP-1 Transcript

HC Wainwright & Co. Maintains Buy on Structure Therapeutics, Lowers Price Target to $100

"Weight Loss Pill from Structure Therapeutics Trimmed The Most Pounds Yet. Is The Biotech A Takeover Candidate?" - Barron's

Structure Therapeutics shares are trading higher after the company announced topline data from the Phase 2 ACCESS clinical program of aleniglipron for the treatment of people living with obesity and/or overweight with at least one weight related co-morbidity.

Structure Therapeutics shares are trading higher after the company announced topline data from the Phase 2 ACCESS clinical program of aleniglipron for the treatment of people living with obesity and/or overweight with at least one weight related co-morbidity.

Structure Therapeutics Announces Positive Top-Line Data From Aleniglipron Weight Treatment ACCESS Clinical Study

Shares of pharmaceutical companies are trading lower amid overall market weakness due to the ongoing conflict in the Middle East.